Upcoming Cell Events

Cell Therapy Analytics Symposium

02 March 2022 |

Online: GMT (UTC+0)

02 March 2022

Online: GMT (UTC+0)

Gene Therapy Development & Manufacturing: In-Person

13 - 14 June 2022 |

London, UK

13 - 14 June 2022

London, UK

+ Digital Day 15 June 2022 | Online

Engage in scientific discussions on the latest tools and technologies for advancing cell therapy analytical development.

3D Cell Culture: In-Person

13-14 September 2022 |

London, UK

13-14 September 2022

London, UK

+ Digital Day: 15 September 2022 | Online

Cell UK: In-Person

07 - 08 November 2022 |

London, UK

07 - 08 November 2022

London, UK

+ Digital Day: 09 November 2022 | Online

Upcoming Discussion Groups

Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing the successful development and manufacture of cell-based products today.

Register below to receive a live stream of the discussion as well a complimentary report outlining the key findings and conclusions covered.

Stem Cell Manufacturing 

09 February 2022 | 15:00 GMT (UTC+0) | 10:00 EST (UTC-4)

Discussion Topics:

  • Presentation: Streamlining Stem Cell Manufacturing by Ajan Reginald, Chief Executive Officer at Celixir
  • 2D vs 3D culture systems
  • Batch sizes
  • Importance of process for phase I
  • Analytical assays


Discussion Group Leaders:

  • Ajan Reginald, Chief Executive Officer, Celixir 
  • Lior Raviv, Chief Technology Officer, Pluristem Therapeutics
  • Glyn Stacey, Gene and Cell Therapy Committee, UK Stem Cell Bank
Cell Line Engineering

Taking place 11 February 2022 | 15:00 GMT (10:00 EST)

Discussion Topics:

  • Presentation: Case Study by Darius Widera, Associate Professor in Stem Cell Biology and Regenerative Medicine, University of Reading 
  • Increasing Clone Selection Efficiency In Cell Line Development 
  • Optimisation of clone generation to ensure more predictable and effective cell line development 
  • Key factors including gene editing technologies, single cell cloning methods, growth media and supplements 

Register to View (Free)

Gene Therapy Manufacturing

Taking place 25 March 2022 | 15:00 GMT (10:00 EST)

Discussion Topics:

  • Presentation: “Cell and Gene Therapy Market Overview”, by Mukesh Mayani, Associate Director – Genomic Medicine CMC at Sanofi 
  • Manufacturing Challenges for Gene Therapy Products: Quality and  Productivity 
  • Strategies for Commercialisation of CGT Therapies: Expansion to Global Markets and Improving Regulatory Alignment


Discussion Panel:

  • Mukesh Mayani, Associate Director – Genomic Medicine CMC, Sanofi 
  • Glyn Stacey, Gene and Cell Therapy Committee, UK Stem Cell Bank  

Register to View (Free)

3D Model Development 

Taking place 27 April 2022 | 15:00 GMT (10:00 EST)

Registration coming soon

Upstream Bioprocessing

Taking place 20 May 2022 | 15:00 GMT (10:00 EST)

Discussion Topics:

Presentation: Industry Overview and Market Trends- Upstream Bioprocessing” by Amir Reza Goudarzi, Head of Process Engineering, UCB Biopharma UK   

  • Analysing the resemblance between cell-therapy and biologics 
  • Facilitating technology transfer for cell-based products
  • Establishing effective and efficient partnerships
  • Case studies on effective technology and knowledge transfer: successes and pitfalls

Discussion Leaders:

  • Amir Reza Goudarzi, Head of Process Engineering, UCB Biopharma UK 
  • Glyn Stacey, Gene and Cell Therapy Committee, UK Stem Cell Bank
  • Williams Olughu, Principal Scientist and BPA Lead, Ipsen 

Register to View (Free)

Cell Therapy Analytics 

Taking place June 23rd 2022 | 15:00 GMT (10:00 EST)

Discussion Topics:

  • Effective Analytics for Allogeneic Cell Therapies 
  • Progression through clinical trials 
  • Development of relevant bioassays for potency, comparability and to identify critical quality attributes (CQAs).  

Discussion Panel:

  • Glyn Stacey, Gene and Cell Therapy Committee, UK Stem Cell Bank  
  • Ajan Reginald, Chief Executive Officer, Celixir 
  • Michael Fossel, President and Founder, Telocyte 

Register to View (Free)

Reports and write-ups pertaining to previous Discussion Groups are available in our Insights section.

Previous Discussion Groups

December 2021

Gene therapy development must be fast and efficient. Automation is one of the main priorities affecting the cell and gene industry today to expedite the next-generation development. By following established platforms consisting of common raw materials, parent cell lines, unit operations, and drug substance formulations, automated processes should deliver an intensified procedure for cell therapy developmentChallenges remain, however, and in our next cell discussion group we bring together an exclusive panel of key opinion leaders to discuss the key factors behind the market’s growth, priorities, future outlook & challenges.

Discussion Points: 

  • Challenges and gaps in technology innovation in cell and gene therapy  
  • Opportunities: transition for available advanced technology in biologics and pharma products to cell and gene therapy  
  • Operational hurdles and how to justify business impact 
  • User requirements and key area of focus (e.g., automation) 
  • Benefits of technology innovation in cell and gene therapy (business impact) 
  • Promoting cross-industry collaboration

Panel Structure: 

  • Moderator: Udayanath Aich, Associate Director, Bristol Myers Squibb 
  • Panellist: Michael Delahaye, Director and Team Leader Cell Therapy Bioprocessing, AstraZeneca 

November 2021

The question of how best to advance technological strategies for viral vector-based gene therapy is an increasingly prevalent and important one. Our first-ever Cell series discussion group aims to delve into the challenges and opportunities of viral vector manufacturing and delivery. This live session brings together experts to look at the latest developments in the field for an hour of a discussion on design and purification techniques, immunogenicity concerns, and characterisation.

Panel Discussion: Bridging The Gap In the Manufacturing Viral Vectors and Viral Vector Based Gene Therapy

  • Designing viral vector delivery to elicit same process
  • Increase yield of viral vectors
    • Purification techniques
  • Immunogenicity concerns
  • Characterisation of viral vectors


John Moscariello, Executive Director Viral Vector and Gene Editing Process Development, Bristol Myers Squibb


Blair Madison, Senior Director, Genetic Engineering, Poseida Therapeutics

Francesca Vitelli, VP, Cell Therapy and AAV Process Development, Intellia Therapeutics

Kyle Grant, Director of Vector Production, Voyager Therapeutics

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Cell